Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BRVE

Braveheart Bio Inc

25.01

Aug 11 • 3:59 PM ET -2.52 (-9.15%)

25.50

Aftermarket • 7:54 PM ET +0.49 (1.96%)

Healthcare Biotechnology USA Small NASD

Held by: TMED

Index	-
Market Cap	1.77B
Enterprise Value	1.84B
Income	-
Sales	-
Book/sh	-1.11
Cash/sh	1.14
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 06, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	21.93
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.11
Current Ratio	8.11
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	-
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-10.95%
SMA50	-10.95%
SMA200	-10.95%
Trades

Shs Outstand	70.65M
Shs Float	38.83M
Short Float	-
Short Ratio	-
Short Interest	-
52W High	32.00 -21.84%
52W Low	27.45 -8.89%
Volatility	- -
ATR (14)	3.37
RSI (14)	-
Beta	-
Rel Volume	0.51
Avg Volume	1.42M
Volume	724,661

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-17.19%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	27.53
Price	25.01
Change %	-9.15%

Aug-07-26 04:05PM

Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

(GlobeNewswire) -8.23%

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

M.D.Dr. Travis Murdoch B.S.

Chief Development OfficerMs. Michele Anderson

Chief Scientific OfficerMr. Marc Evanchik M.S.

VP & Head of LegalMs. Natalie Dement J.D.

Director of Corporate DevelopmentMr. Timothy Y. Zhou

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AH Bio Fund IV, L.P.	10% Owner	Aug 07 '26	Buy	18.00	1,100,000	19,800,000	10,232,420	Aug 11 05:53 PM
Chimovits Erez	Director	Aug 07 '26	Buy	18.00	1,940,000	34,920,000	11,901,826	Aug 11 05:31 PM
ORBIMED ADVISORS LLC	Director	Aug 07 '26	Buy	18.00	1,940,000	34,920,000	11,901,826	Aug 11 05:27 PM
Forbion Growth Opportunities F	10% Owner	Aug 07 '26	Buy	18.00	1,920,000	34,560,000	11,640,546	Aug 07 05:25 PM
Forbion Growth Opportunities F	10% Owner	Aug 07 '26	Buy	18.00	1,680,000	30,240,000	10,185,478	Aug 07 05:25 PM
Rickey James Paul	Chief Financial Officer	Aug 07 '26	Buy	18.00	27,777	499,986	520,927	Aug 07 04:41 PM
Viehbacher Christopher	Director	Aug 07 '26	Buy	18.00	83,333	1,499,994	609,519	Aug 07 04:31 PM
Malek David I	Director	Aug 07 '26	Buy	18.00	4,166	74,988	533,845	Aug 07 04:31 PM
Anderson Michele A.	Chief Development Officer	Aug 07 '26	Buy	18.00	1,111	19,998	332,161	Aug 07 04:30 PM
Murdoch Travis	CEO and President	Aug 07 '26	Buy	18.00	83,333	1,499,994	2,940,670	Aug 07 04:30 PM
Lubner David Charles	Director	Aug 07 '26	Buy	18.00	55,555	999,990	55,555	Aug 07 04:30 PM

Open in Screener

UPB

Upstream Bio Inc

7.09

Aug 11 • 3:59 PM ET -0.35 (-4.70%)

7.09

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: INCY BMRN KRYS KYMR RYTM CRNX AXSM MDGL VKTX NBIX

| Held by: VTI IWM VXF IWN IBB VTWO SCHA DFAS AVSC DFMC

Index	RUT
Market Cap	385.83M
Enterprise Value	92.36M
Income	-156.76M
Sales	3.32M
Book/sh	5.59
Cash/sh	5.41
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	75
IPO	Oct 11, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	116.21
P/B	1.27
P/C	1.31
P/FCF	-
EV/EBITDA	-
EV/Sales	27.82
Quick Ratio	23.14
Current Ratio	23.14
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.90
EPS next Y	-2.81
EPS next Q	-0.72
EPS this Y	-7.95%
EPS next Y	2.19%
EPS next 5Y	-4.45%
EPS past 3/5Y	-81.53% -
Sales past 3/5Y	33.04% -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-46.95%
Sales Q/Q	82.69%
Earnings	May 13 BMO
EPS/Sales Surpr.	0.05% 0.61%

Insider Own	33.43%
Insider Trans	-0.06%
Inst Own	65.51%
Inst Trans	-10.28%
ROA	-40.50%
ROE	-41.83%
ROIC	-51.50%
Gross Margin	94.16%
Oper. Margin	-5176.49%
Profit Margin	-4718.96%
SMA20	4.60%
SMA50	3.34%
SMA200	-54.10%
Trades

Shs Outstand	54.42M
Shs Float	36.23M
Short Float	10.07%
Short Ratio	5.91
Short Interest	3.65M
52W High	33.68 -78.95%
52W Low	5.85 21.20%
Volatility	6.64% 5.81%
ATR (14)	0.42
RSI (14)	53.69
Beta	1.38
Rel Volume	1.02
Avg Volume	617.75K
Volume	628,055

Perf Week	4.42%
Perf Month	-2.61%
Perf Quarter	-22.17%
Perf Half Y	-72.86%
Perf YTD	-73.89%
Perf Year	-57.26%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.44
Target Price	35.86
Prev Close	7.44
Price	7.09
Change %	-4.70%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-12-26	Downgrade	JP Morgan	Overweight → Neutral	$8
Jun-03-26	Initiated	H.C. Wainwright	Buy	$36
Mar-27-26	Downgrade	Evercore ISI	Outperform → In-line	$15
Dec-18-25	Initiated	Mizuho	Outperform	$51
Nov-18-25	Initiated	Evercore ISI	Outperform	$40
Oct-14-25	Initiated	Truist	Buy	$47
Nov-05-24	Initiated	William Blair	Outperform
Nov-05-24	Initiated	TD Cowen	Buy
Nov-05-24	Initiated	Piper Sandler	Overweight	$75
Nov-05-24	Initiated	JP Morgan	Overweight	$38

Today 07:00AM	Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress (GlobeNewswire)
Jun-14-26 10:00AM	Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 (GlobeNewswire)
Jun-08-26 07:00AM	Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 (GlobeNewswire) -8.51%
Jun-03-26 07:00AM	Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire) +5.24%
May-18-26 11:30AM	Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference (GlobeNewswire) -6.38%
07:00AM	Loading…
May-13-26 07:00AM	Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-17-26 07:00AM	Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference (GlobeNewswire)
Mar-27-26 09:46AM	Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls (The Fly) -11.44%
Mar-26-26 07:00AM	Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-01-26 09:45AM	Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting (GlobeNewswire)
Feb-26-26 07:00AM	Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 (GlobeNewswire)
Feb-25-26 07:00AM	Upstream Bio to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-15-26 07:11PM	Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56% (MarketBeat)
Feb-13-26 10:45AM	Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns (Benzinga) -31.64%
Feb-12-26 07:55AM	Upstream Bios stock drops 47% on verekitug Phase II asthma data (Clinical Trials Arena) -12.87%
09:57AM	Loading…
Feb-11-26 09:57AM	Upstream Bio Crashes After Asthma Drug Succeeds - With The Wrong Dose (Investor's Business Daily) -47.18%
09:02AM	Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts (Benzinga)
06:00AM	Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma (GlobeNewswire)
04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 06:00PM	Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma (GlobeNewswire) +6.47%
Jan-05-26 07:00AM	Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-25-25 07:00AM	Upstream Bio to Participate in Upcoming December Investor Conferences (GlobeNewswire) +10.67%
Nov-05-25 07:00AM	Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress (GlobeNewswire)
Oct-31-25 07:00AM	Upstream Bio to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-16-25 04:33PM	Upstream Bio Presents New Structural Data on Verekitug, Highlights Unique TSLP Receptor Targeting (Insider Monkey) -5.88%
Sep-30-25 04:15AM	Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress (GlobeNewswire) +8.48%
Sep-16-25 01:59PM	Upstream Bio, Inc. (UPB): A Bull Case Theory (Insider Monkey)
Sep-09-25 07:00AM	Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Sep-02-25 06:00AM	Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (GlobeNewswire) +18.27%
Sep-01-25 05:00PM	Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (GlobeNewswire)
12:13AM	Loading…
Aug-20-25 12:13AM	Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug (Insider Monkey)
Aug-06-25 07:00AM	Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress (GlobeNewswire) +7.87%
Jul-09-25 09:00AM	First subject dosed in Upstream Bios Phase II trial of verekitug for COPD (Clinical Trials Arena) +7.34%
Jul-08-25 07:00AM	Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) (GlobeNewswire)
Jun-15-25 07:45AM	Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor (GlobeNewswire)
Jun-05-25 07:00AM	Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 (GlobeNewswire)
Jun-04-25 07:00AM	Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-20-25 07:00AM	Upstream Bio Appoints Stacy Price as Chief Technology Officer (GlobeNewswire)
May-06-25 07:00AM	Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs (GlobeNewswire) -5.41%
Apr-17-25 05:51PM	Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent (Seeking Alpha) +10.59%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-12-25 07:00AM	Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +7.83%
Feb-25-25 08:00AM	Upstream Bio to Present at Upcoming March Investor Conferences (GlobeNewswire) -5.96%
Feb-11-25 09:00AM	Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps (PR Newswire)
Jan-06-25 08:00AM	Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.47%
Dec-17-24 08:00AM	Upstream Bio Appoints Allison Ambrose as General Counsel (GlobeNewswire)
Dec-16-24 08:00AM	Upstream Bio Announces Addition to Russell 2000 Index (GlobeNewswire) -6.12%
Nov-21-24 08:00AM	Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 07:11AM	Upstream Bio reports Q3 revenue $607,000 vs $621,000 last year (TipRanks)
Nov-07-24 07:00AM	Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-17-24 07:02PM	Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc (GuruFocus.com) +9.66%
Oct-15-24 04:15PM	Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +6.27%
Oct-10-24 07:35PM	Upstream Bio Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

M.P.H.Dr. E. Rand Sutherland M.D.

MBAMr. Michael Paul Gray CPA

Chief Medical Officer and Head of Research & DevelopmentMr. Aaron Deykin M.D.

P.M.P.Ms. Stacy Price M.S.

Director of Corporate Communications & Investor RelationsMeggan Buckwell

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GRAY MICHAEL	CFO and COO	Jun 16 '26	Sale	6.10	853	5,203	28,795	Jun 17 04:05 PM
Sutherland Everett Rand	Chief Executive Officer	Jun 16 '26	Sale	6.10	2,095	12,780	70,812	Jun 17 04:05 PM
Houghton Adam	Chief Business Officer	Jun 16 '26	Sale	6.10	700	4,270	23,601	Jun 17 04:05 PM
Deykin Aaron	Chief Medical Officer	Jun 16 '26	Sale	6.10	895	5,460	33,197	Jun 17 04:05 PM
Ambrose Allison	General Counsel	Jun 16 '26	Sale	6.10	477	2,910	16,048	Jun 17 04:05 PM
GRAY MICHAEL	CFO and COO	Mar 16 '26	Sale	9.29	852	7,915	29,648	Mar 17 05:03 PM
Deykin Aaron	Chief Medical Officer	Mar 16 '26	Sale	9.29	894	8,305	32,687	Mar 17 05:02 PM
Sutherland Everett Rand	Chief Executive Officer	Mar 16 '26	Sale	9.29	2,093	19,444	72,907	Mar 17 05:00 PM
Ambrose Allison	General Counsel	Mar 16 '26	Sale	9.29	475	4,413	16,525	Mar 17 05:00 PM
Houghton Adam	Chief Business Officer	Mar 16 '26	Sale	9.29	699	6,494	24,301	Mar 17 04:59 PM

BRVE

Braveheart Bio Inc

UPB

Upstream Bio Inc

Upgrade your Finviz experience